The raised INGREZZA guidance and strong VYKAT XR launch validate the Soleno acquisition thesis. Watch for the December 15 R&D Day for updates on Phase 3 readouts for osavampator (MDD) and direclidine (schizophrenia), which are key pipeline catalysts for 2027.
Drugs in focus
NBIX drug pipeline →direclidine
● Neutral Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 trials succeed, a potential FDA submission could occur in 2028, with approval possible in 2029 at the earliest, assuming topline data reads out in 2027 and a standard ~12-month review cycle.
- Next catalyst
- None dated
What to watchThe next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $164.85entry
- T+1 · 13d ago +0.73%α −0.92% · $166.05
- T+5 · 7d ago +2.60%α +3.19% · $169.14
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up 41% YoY, with net product sales exceeding $1B for the first time. INGREZZA net sales guidance was raised to $2.9B-$2.925B from $2.825B-$2.875B. Non-GAAP EPS of $3.29 beat the $2.75 consensus, and revenue of $1.123B beat the $1.04B consensus.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $1.123B, up 41% YoY from $795M
- INGREZZA net product sales $801M, up 17% YoY
- CRENESSITY net product sales $211M, up 115% YoY
- VYKAT XR net product sales $107M (first contribution from Soleno acquisition)
- INGREZZA full-year 2026 guidance raised to $2.9B-$2.925B
- Non-GAAP EPS $3.29 vs consensus $2.75 (beat)
- GAAP EPS $1.96 vs $2.04 in prior year (decline due to acquisition-related costs and equity investment losses)
- Cash and marketable securities $790M at quarter end, down from $2.543B at Dec 2025 due to Soleno acquisition
Financial Impact
Revenue beat consensus by ~$83M (8%); Non-GAAP EPS beat consensus by $0.54 (19.6%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| INGREZZA | $801.0M | +17.0% |
| CRENESSITY | $211.0M | +115.0% |
| VYKAT XR | $107.0M | Not reported |
Risk Factors
- GAAP net income declined YoY due to acquisition-related costs and $52M equity investment loss
- Cash balance significantly reduced from $2.543B to $790M following Soleno acquisition
- Integration of Soleno and VYKAT XR commercial execution still in early stages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000914475-26-000053 |
| Document: nbix-20261102.htm | 0000914475-26-000053 |
| Document: 0000914475-26-000053-index-headers.html | 0000914475-26-000053 |
| Document: 0000914475-26-000053-index.html | 0000914475-26-000053 |
| Document: 0000914475-26-000053.txt | 0000914475-26-000053 |
| 8-K Data (Synthetic) | 0000914475-26-000053 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers